Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.
Continue reading this article about Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
by Jane Kirby
NHS Forums - For daily discussion by NHS Staff.

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.
Continue reading this article about Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
by Jane Kirby
NHS Forums - For daily discussion by NHS Staff.